Leerink Partnrs Issues Optimistic Forecast for A Earnings

Agilent Technologies, Inc. (NYSE:A) – Research analysts at Leerink Partnrs upped their Q3 2025 earnings estimates for shares of Agilent Technologies in a report issued on Wednesday, December 18th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings per share of $1.42 for the quarter, up from their prior forecast of $1.41. The consensus estimate for Agilent Technologies’ current full-year earnings is $5.56 per share. Leerink Partnrs also issued estimates for Agilent Technologies’ Q1 2026 earnings at $1.49 EPS, Q2 2026 earnings at $1.43 EPS, Q3 2026 earnings at $1.52 EPS and Q4 2026 earnings at $1.66 EPS.

Agilent Technologies (NYSE:A) last posted its earnings results on Monday, November 25th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.41 by $0.05. Agilent Technologies had a return on equity of 25.43% and a net margin of 19.80%. The company had revenue of $1.70 billion during the quarter, compared to analysts’ expectations of $1.67 billion. During the same quarter last year, the firm earned $1.38 earnings per share. The firm’s quarterly revenue was up .8% compared to the same quarter last year.

Several other equities analysts have also commented on A. Sanford C. Bernstein decreased their price objective on shares of Agilent Technologies from $140.00 to $135.00 and set a “market perform” rating on the stock in a report on Tuesday, November 26th. Bank of America dropped their price objective on Agilent Technologies from $153.00 to $150.00 and set a “neutral” rating for the company in a research note on Friday, December 13th. Evercore ISI increased their target price on Agilent Technologies from $135.00 to $145.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Wells Fargo & Company lowered their target price on Agilent Technologies from $157.00 to $155.00 and set an “overweight” rating for the company in a report on Monday, December 9th. Finally, JPMorgan Chase & Co. cut their price target on shares of Agilent Technologies from $165.00 to $160.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, six have assigned a hold rating and eight have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Agilent Technologies currently has an average rating of “Hold” and an average price target of $143.62.

Agilent Technologies Trading Up 1.1 %

NYSE A opened at $136.10 on Monday. The company has a debt-to-equity ratio of 0.57, a current ratio of 2.09 and a quick ratio of 1.58. The stock has a market capitalization of $39.11 billion, a P/E ratio of 30.79, a PEG ratio of 4.48 and a beta of 1.07. The firm’s 50-day moving average is $135.66 and its two-hundred day moving average is $136.51. Agilent Technologies has a 12 month low of $124.16 and a 12 month high of $155.35.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Van ECK Associates Corp raised its stake in shares of Agilent Technologies by 6.6% during the third quarter. Van ECK Associates Corp now owns 2,976,905 shares of the medical research company’s stock worth $442,011,000 after purchasing an additional 183,716 shares during the last quarter. AXA S.A. raised its position in Agilent Technologies by 32.3% during the 2nd quarter. AXA S.A. now owns 362,945 shares of the medical research company’s stock worth $47,049,000 after buying an additional 88,667 shares during the last quarter. Vestal Point Capital LP acquired a new stake in shares of Agilent Technologies in the 3rd quarter worth $14,848,000. Empowered Funds LLC boosted its holdings in shares of Agilent Technologies by 29.8% in the third quarter. Empowered Funds LLC now owns 30,978 shares of the medical research company’s stock valued at $4,592,000 after acquiring an additional 7,111 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA increased its stake in shares of Agilent Technologies by 5.7% during the second quarter. Massachusetts Financial Services Co. MA now owns 15,064,660 shares of the medical research company’s stock worth $1,952,832,000 after acquiring an additional 809,149 shares during the period. 87.42% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, SVP Dominique Grau sold 9,990 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $145.00, for a total value of $1,448,550.00. Following the completion of the sale, the senior vice president now owns 40,011 shares in the company, valued at $5,801,595. This represents a 19.98 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.33% of the company’s stock.

Agilent Technologies Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 22nd. Shareholders of record on Tuesday, December 31st will be paid a $0.248 dividend. This represents a $0.99 annualized dividend and a yield of 0.73%. The ex-dividend date of this dividend is Tuesday, December 31st. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.24. Agilent Technologies’s dividend payout ratio is currently 22.40%.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.